Poolbeg Pharma PLC PredictViral Patent Update (0166P)
14 Octubre 2021 - 1:00AM
UK Regulatory
TIDMPOLB
RNS Number : 0166P
Poolbeg Pharma PLC
14 October 2021
Poolbeg Pharma plc
PredictViral(TM) Patent update
14 October 2021 - Poolbeg Pharma (AIM: POLB), 'Poolbeg' or the
'Company', a clinical stage infectious disease pharmaceutical
company with a capital light clinical model, provides an update on
new patent filings for its PredictViral(TM) platform that estimates
disease severity and contagiousness in people who are recently
infected with a respiratory virus.
Expanding on existing PredictViral(TM) IP, these latest patent
applications have been submitted in the UK and aims to protect a
method of predicting whether an individual exposed to a respiratory
virus (such as Influenza, RSV, hRV) will have a higher severity of
disease and / or be more likely to be contagious. The Company will
continue to focus on expanding its IP portfolio as required.
hVIVO (part of Open Orphan plc ) filed these predictive
biomarker patent applications on behalf of Poolbeg and as agreed as
part of the demerger process and as outlined in Poolbeg's IPO
Admission Document, ownership will ultimately reside with Poolbeg
which will continue to commercialise the platform. This will
provide clinicians with a risk score for recently infected patients
who are likely to experience a severe form of disease. Identifying
viral infections early and triaging patients based on likely
severity is vitally important in optimising clinical outcomes and
can be particularly important in diseases such as influenza where
there is a limited window for successful treatment early in the
disease. The Company will continue to focus on expanding its IP
portfolio as required.
Poolbeg Pharma believes that the PredictViral(TM) platform
offers diagnostic companies a transformative product that will
enhance clinical decision-making while differentiating their
platforms at a time of intense competition in this market.
Discussions are ongoing with multiple parties to continue this
technology's development and license it for commercial use. The
global market for diagnostic tools for infectious disease is
rapidly growing and is expected to be worth over $19 billion per
annum by 2025.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma said:
"Protecting the IP for such an innovative disease severity
platform as PredictViral(TM) is important and key to our strategy
of commercialising this cutting-edge technology.
PredictViral(TM) will provide valuable information for assessing
the best course of treatment for viral disease. It has the
potential to help early interventions when needed and to reduce the
spread of disease, even amongst those who are unaware they are
infected - the importance of which has become very clear during the
COVID-19 global pandemic."
- Ends -
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +353 (0) 1 644 0007
finnCap Ltd (Nominated Adviser & Joint
Broker)
Geoff Nash, James Thompson, Charlie
Beeson +44 (0) 20 7220 0500
Arden Partners PLC (Joint Broker)
John Lewellyn-Lloyd, Louisa Waddell,
Oscair McGrath +44 (0) 207 614 5900
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Instinctif Partners +44 (0) 20 7457 2020
Melanie Toyne Sewell, Rozi Morris, Tim poolbeg@instinctif.com
Field
About Poolbeg Pharma
Poolbeg Pharma is a clinical stage infectious disease
pharmaceutical company, with a capital light clinical model which
aims to develop multiple products faster and more cost effectively
than the conventional biotech model. The Company, headquartered in
London, is led by a team with a track record of creation and
delivery of shareholder value and aspires to become a "one-stop
shop" for Big Pharma seeking mid-stage products to licence or
acquire.
The Company is targeting the growing infectious disease market.
In the wake of the COVID-19 pandemic, infectious disease has become
one of the fastest growing pharma markets and is expected to exceed
$250bn by 2025.
With its initial assets from Open Orphan plc, an industry
leading infectious disease and human challenge trials business,
Poolbeg has access to knowledge, experience, and clinical data from
over 20 years of human challenge trials. The Company is using these
insights to acquire new assets as well as reposition clinical stage
products, reducing spend and risk. It already has a Phase II ready
repositioned small molecule immunomodulator for severe influenza
and a portfolio of other exciting assets. The Company plans to
broaden this portfolio further going forward and is in active
discussions with AI data analysis platforms to help accelerate the
power of its human challenge model data and biobank.
For more information, please go to www.poolbegpharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFSAIELVLIL
(END) Dow Jones Newswires
October 14, 2021 02:00 ET (06:00 GMT)
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024